结直肠癌治疗市场基于(主要地区、市场参与者、规模和份额)- 预测至 2030 年

  • Report Code : TIPRE00038988
  • Category : Medical Device
  • No. of Pages : 150
Buy Now

Colorectal Cancer Treatment Market Size & Forecast by 2030

Buy Now

【研究报告】2022年结直肠癌治疗市场规模为188.10亿美元,预计到2030年将达到239.78亿美元,预计2022-2030年复合年增长率为3.1%。
市场洞察和分析师观点:
市场规模的增长归因于结直肠癌病例数量的增加以及用于治疗结直肠癌的靶向治疗和免疫疗法的批准增加。此外,公司为保持市场竞争力而采取的战略举措也推动了市场的增长。为满足客户对结直肠癌治疗的需求,个性化药物的大幅增长可能会在预测期内带来新的结直肠癌治疗市场趋势。
增长动力和挑战:
结直肠癌是一种发生的恶性肿瘤。在结肠或直肠组织中。水果和蔬菜摄入量低、吸烟成瘾、久坐的生活方式、肥胖、加工肉类摄入量高以及过量饮酒等生活方式因素导致结直肠癌病例的增加。它是美国每年诊断出的第三种最常见的癌症(不包括皮肤癌)。 2023年,世界卫生组织(WHO)表示,结直肠癌是全球第三大常见癌症,也是全球癌症相关死亡的第二大原因。根据同一来源,全球诊断的总病例中约 10% 是结直肠癌病例。据美国癌症协会估计,2023年美国将新增约106,000例结肠癌和约46,000例直肠癌新发病例。
根据欧洲癌症信息系统提供的数据,结直肠癌约占12.7%在欧盟 27 个国家,2020 年诊断的所有新癌症中的 %,以及 2020 年总死亡率的约 12.4% 是由结直肠癌引起的。由于发病率高,结直肠癌是继乳腺癌之后第二大常见癌症,也是继肺癌之后癌症相关死亡的第二大原因。根据国际癌症研究机构和 GLOBOCAN 的数据,2020 年亚洲报告了约 100 万新结直肠癌病例。与亚洲其他国家相比,日本、马来西亚、中国、新加坡、土耳其和韩国的患病率较高太平洋。此外,到2040年,全球结直肠癌负担预计将增加72%,新发病例将超过300万例,对人类健康构成严重威胁。因此,结直肠癌发病率的上升推动了结直肠癌治疗市场的增长。

报告细分和范围:
结直肠癌治疗市场分析是通过考虑以下细分进行的:治疗类型、年龄组、最终用户和地理位置。结直肠癌治疗市场按治疗类型分为手术、化疗、靶向治疗、免疫治疗等。根据年龄层,市场分为49岁以下、50-64岁、65岁以上。按最终用户划分,市场分为医院、专科诊所、家庭护理等。结直肠癌治疗市场报告的范围涉及北美(美国、加拿大和墨西哥)、欧洲(西班牙、英国、德国、法国、意大利和欧洲其他地区)、亚太地区(韩国、中国、日本、印度、澳大利亚和亚太其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)。
细分分析:
结直肠癌治疗市场按治疗类型分为手术、化疗、靶向治疗、免疫治疗等。 2022年,手术细分市场占据最大的结直肠癌治疗市场份额,预计2022-2030年将创下最高复合年增长率。手术被认为是所有阶段结直肠癌最常见的治疗方法。如果在早期诊断出癌症,则进行手术切除肿瘤。
根据年龄组,市场分为 49 岁以下、50-64 岁和 65 岁以上。 2022年,65岁以上细分市场占据最大的结直肠癌治疗市场份额,预计2022年至2030年期间复合年增长率最高。根据美国癌症协会的报告,估计美国一半以上的新诊断病例年龄在 65 岁以上,所有结直肠癌死亡人数中超过三分之二是年龄在 65 岁以上的人。 br>根据最终用户,市场分为医院、专科诊所、家庭护理等。医院领域的结直肠癌治疗市场规模可能会在 2022 年至 2030 年期间激增。
按治疗类型划分的结直肠癌治疗市场 – 2022 年和 2030 年
区域分析:
北美是最大的贡献者全球结直肠癌治疗市场的增长。预计 2022 年至 2030 年,亚太地区的市场复合年增长率将最高。由于结直肠癌数量不断增加、技术不断进步、50岁以下人群结直肠癌患病率较高,以及参与新产品和现有产品开发的主要市场参与者的存在,北美在2022年将占据全球市场的最大份额。在北美,美国在 2022 年占据最大的市场份额。
行业发展和未来机遇:
结直肠癌治疗市场预测是根据各种二级和一级研究结果(例如主要公司)估计的出版物、协会数据和数据库。结直肠癌治疗市场主要参与者的策略如下:
2023 年 11 月,武田制药宣布其口服靶向治疗药物 FRUZAQLA (FRUZAQLA) 已获得美国食品和药物管理局 (FDA) 的批准。呋喹替尼)用于治疗患有转移性结直肠癌(mCRC)的成人。 FRUZAQLA 是第一个也是唯一一个在美国批准用于治疗 mCRC 的所有三种 VEGF 受体激酶的选择性抑制剂,无论生物标志物状态如何。 2023 年 8 月,Taiho Pharmaceutical Co., Ltd 宣布美国 FDA 已批准 LONSURF (曲氟尿苷/替匹拉西)作为单一药物并与贝伐单抗联合用于治疗患有转移性结直肠癌的成年患者。这些患者之前接受过基于奥沙利铂、氟嘧啶和伊立替康的化疗(一种抗 VEGF 生物疗法)。竞争格局和主要公司:
Genentech Inc、Eli Lilly and Company、Pfizer Inc、Takeda Pharmaceuticals、Bristol Myers施贵宝、默克、拜耳公司、再生元制药公司、诺华公司和易普森生物制药公司是结直肠癌治疗市场报告中介绍的知名参与者。此外,研究期间还对其他几家参与者进行了研究和分析,以全面了解市场及其生态系统。这些公司专注于地域扩张和新产品发布,以满足全球消费者不断增长的需求,并增加其专业产品组合的产品范围。他们的全球业务使他们能够为庞大的客户群提供服务,从而促进市场扩张。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Who are the major players in market the colorectal cancer treatment market?

The colorectal cancer treatment market majorly consists of the players such Genentech Inc, Eli Lilly and Company, Pfizer Inc, Takeda Pharmaceuticals, Bristol Myers Squibb, Merck, Bayer AG, Regeneron Pharmaceuticals Inc, Novartis AG, and Ipsen Biopharmaceuticals Inc.

Which region is dominating the colorectal cancer treatment market?

Based on geography, the colorectal cancer treatment market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global colorectal cancer treatment market. Asia Pacific is expected to register the highest CAGR in the colorectal cancer treatment market during 2022–2030.

What is colorectal cancer treatment?

Colorectal cancer often begins as a growth called a polyp inside the colon or rectum. Colorectal cancer happens when there are changes in genetic material (DNA). These changes are also called mutations or variants. Often, the genetic changes that lead to colorectal cancer happen during lifetime and the exact cause is unknown. Colorectal cancer treatment includes surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, cryosurgery, and radiofrequency ablation.

What are the driving and restraining factors for the colorectal cancer treatment market?

The growing number of colorectal cancer cases and the subsequent increase in product launches are factors predominantly driving the colorectal cancer treatment market size. However, the high cost associated with colorectal cancer treatment in developing countries hinders the market growth.

Which segment is dominating the colorectal cancer treatment market?

The colorectal cancer treatment market, by treatment type, is segmented into surgery, chemotherapy, targeted therapy, immunotherapy, and others. In 2022, the surgery segment held the largest colorectal cancer treatment market share and is expected to record the highest CAGR during 2022–2030.
Based on age group, the market is segmented into below 49 years, 50–64 years, and above 65 years. In 2022, the above 65 years segment held the largest colorectal cancer treatment market share and is projected to record the highest CAGR during 2022–2030.
Based on end user, the market is divided into hospitals, specialty clinics, home care, and others. The colorectal cancer treatment market size for the hospital segment is likely to surge during 2022–2030.

The List of Companies - Colorectal Cancer Treatment Market 

  1. Genentech Inc
  2. Eli Lilly and Company
  3. Pfizer Inc
  4. Takeda Pharmaceuticals
  5. Bristol Myers Squibb
  6. Merck
  7. Bayer AG
  8. Regeneron Pharmaceuticals Inc
  9. Novartis AG
  10. Ipsen Biopharmaceuticals

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports